Navigation Links
LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue
Date:10/21/2010

MADISON, Wis., Oct. 21 /PRNewswire/ -- LifeGen Technologies, LLC has been awarded a Phase I Small Business Innovative Research grant from the United States National Institute on Aging. The project is focused on identifying a robust panel of genes in adipose tissue (fat) that are regulated by a calorie restricted diet. According to Dr. Jamie Barger, Director of Operations at LifeGen, the technology developed under the NIH grant will allow LifeGen to screen for compounds that have beneficial effects on adipose tissue in a manner similar to that of a calorie restricted diet.

Caloric restriction is the only dietary intervention proven to increase both maximum and average lifespan in mammals, as well delaying age-related diseases. Because caloric restriction reduces body fat and markers of inflammation related to disease, it is thought that metabolic alterations in fat may underlie many of the health benefits associated with this dietary intervention.  "Several decades of research support the concept of caloric restriction as an effective intervention in aging retardation. This research grant clearly validates the enormous potential of LifeGen's technology in discovering the next generation of anti-aging compounds, based on caloric restriction science," said LifeGen cofounder and Chief Scientific Officer Dr. Tomas A. Prolla.

ABOUT LIFEGEN TECHNOLOGIES, LLC: LifeGen was co-founded in November 2000 by Drs. Richard Weindruch and Tomas A. Prolla, professors at the University of Wisconsin-Madison and leaders in the fields of gerontology and genetics. Drs. Prolla and Weindruch were the first scientists to use DNA microarrays to measure gene activity in mammalian tissues.

LifeGen Technologies is using gene expression technology to study how the aging process is retarded by caloric restriction (CR), the only intervention proven to increase maximum lifespan and retard aging in a diverse array of species. LifeGen has licensed technology from the University of Wisconsin for the use of such "gene expression profiling" as a method to measure the progression of the aging process at the molecular level in individual organs. This technology has been used to identify several "supermarkers" of both aging and caloric restriction, which are currently being used for compound screening.

More information is available at: http://www.lifegentech.com

CONTACT:  Jamie Barger, +1-608-886-6776, Jamie.L.Barger@gmail.com


'/>"/>
SOURCE LifeGen Technologies, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
2. Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype
3. Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters
4. Reportlinker Adds US Forensic Technologies and Services Industry
5. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
6. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
7. Wireless Health 2010 Explores the Roles of Wireless Technologies in Clinical Services
8. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
9. BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium
10. RF Technologies® Names Mark Harwood New President
11. IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):